Literature DB >> 29278423

Exercise for intermittent claudication.

Risha Lane1, Amy Harwood, Lorna Watson, Gillian C Leng.   

Abstract

BACKGROUND: Exercise programmes are a relatively inexpensive, low-risk option compared with other, more invasive therapies for treatment of leg pain on walking (intermittent claudication (IC)). This is the fourth update of a review first published in 1998.
OBJECTIVES: Our goal was to determine whether an exercise programme was effective in alleviating symptoms and increasing walking treadmill distances and walking times in people with intermittent claudication. Secondary objectives were to determine whether exercise was effective in preventing deterioration of underlying disease, reducing cardiovascular events, and improving quality of life. SEARCH
METHODS: For this update, the Cochrane Vascular Information Specialist searched the Specialised Register (last searched 15 November 2016) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 10) via the Cochrane Register of Studies Online, along with trials registries. SELECTION CRITERIA: Randomised controlled trials of an exercise regimen versus control or versus medical therapy for people with IC due to peripheral arterial disease (PAD). We included any exercise programme or regimen used for treatment of IC, such as walking, skipping, and running. Inclusion of trials was not affected by duration, frequency, or intensity of the exercise programme. Outcome measures collected included treadmill walking distance (time to onset of pain or pain-free walking distance and maximum walking time or maximum walking distance), ankle brachial index (ABI), quality of life, morbidity, or amputation; if none of these was reported, we did not include the trial in this review. DATA COLLECTION AND ANALYSIS: For this update (2017), RAL and AH selected trials and extracted data independently. We assessed study quality by using the Cochrane 'Risk of bias' tool. We analysed continuous data by determining mean differences (MDs) and 95% confidence intervals (CIs), and dichotomous data by determining risk ratios (RRs) and 95% CIs. We pooled data using a fixed-effect model unless we identified significant heterogeneity, in which case we used a random-effects model. We used the GRADE approach to assess the overall quality of evidence supporting the outcomes assessed in this review. MAIN
RESULTS: We included two new studies in this update and identified additional publications for previously included studies, bringing the total number of studies meeting the inclusion criteria to 32, and involving a total of 1835 participants with stable leg pain. The follow-up period ranged from two weeks to two years. Types of exercise varied from strength training to polestriding and upper or lower limb exercises; supervised sessions were generally held at least twice a week. Most trials used a treadmill walking test for one of the primary outcome measures. The methodological quality of included trials was moderate, mainly owing to absence of relevant information. Most trials were small and included 20 to 49 participants. Twenty-seven trials compared exercise versus usual care or placebo, and the five remaining trials compared exercise versus medication (pentoxifylline, iloprost, antiplatelet agents, and vitamin E) or pneumatic calf compression; we generally excluded people with various medical conditions or other pre-existing limitations to their exercise capacity.Meta-analysis from nine studies with 391 participants showed overall improvement in pain-free walking distance in the exercise group compared with the no exercise group (MD 82.11 m, 95% CI 71.73 to 92.48, P < 0.00001, high-quality evidence). Data also showed benefit from exercise in improved maximum walking distance (MD 120.36 m, 95% CI 50.79 to 189.92, P < 0.0007, high-quality evidence), as revealed by pooling data from 10 studies with 500 participants. Improvements were seen for up to two years.Exercise did not improve the ABI (MD 0.04, 95% CI 0.00 to 0.08, 13 trials, 570 participants, moderate-quality evidence). Limited data were available for the outcomes of mortality and amputation; trials provided no evidence of an effect of exercise, when compared with placebo or usual care, on mortality (RR 0.92, 95% CI 0.39 to 2.17, 5 trials, 540 participants, moderate-quality evidence) or amputation (RR 0.20, 95% CI 0.01 to 4.15, 1 trial, 177 participants, low-quality evidence).Researchers measured quality of life using Short Form (SF)-36 at three and six months. At three months, the domains 'physical function', 'vitality', and 'role physical' improved with exercise; however this was a limited finding, as it was reported by only two trials. At six months, meta-analysis showed improvement in 'physical summary score' (MD 2.15, 95% CI 1.26 to 3.04, P = 0.02, 5 trials, 429 participants, moderate-quality evidence) and in 'mental summary score' (MD 3.76, 95% CI 2.70 to 4.82, P < 0.01, 4 trials, 343 participants, moderate-quality evidence) secondary to exercise. Two trials reported the remaining domains of the SF-36. Data showed improvements secondary to exercise in 'physical function' and 'general health'. The other domains - 'role physical', 'bodily pain', 'vitality', 'social', 'role emotional', and 'mental health' - did not show improvement at six months.Evidence was generally limited in trials comparing exercise versus antiplatelet therapy, pentoxifylline, iloprost, vitamin E, and pneumatic foot and calf compression owing to small numbers of trials and participants.Review authors used GRADE to assess the evidence presented in this review and determined that quality was moderate to high. Although results showed significant heterogeneity between trials, populations and outcomes were comparable overall, with findings relevant to the claudicant population. Results were pooled for large sample sizes - over 300 participants for most outcomes - using reproducible methods. AUTHORS'
CONCLUSIONS: High-quality evidence shows that exercise programmes provided important benefit compared with placebo or usual care in improving both pain-free and maximum walking distance in people with leg pain from IC who were considered to be fit for exercise intervention. Exercise did not improve ABI, and we found no evidence of an effect of exercise on amputation or mortality. Exercise may improve quality of life when compared with placebo or usual care. As time has progressed, the trials undertaken have begun to include exercise versus exercise or other modalities; therefore we can include fewer of the new trials in this update.

Entities:  

Mesh:

Year:  2017        PMID: 29278423      PMCID: PMC6486315          DOI: 10.1002/14651858.CD000990.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  199 in total

1.  Predictors of treatment outcome in intermittent claudication.

Authors:  C Taft; M Sullivan; K Lundholm; J Karlsson; J Gelin; L Jivegård
Journal:  Eur J Vasc Endovasc Surg       Date:  2004-01       Impact factor: 7.069

2.  Plasma nitrite flux predicts exercise performance in peripheral arterial disease after 3months of exercise training.

Authors:  Jason D Allen; Thomas Stabler; Aarti Kenjale; Katherine L Ham; Jennifer L Robbins; Brian D Duscha; Devon A Dobrosielski; Brian H Annex
Journal:  Free Radic Biol Med       Date:  2010-07-08       Impact factor: 7.376

3.  A randomised controlled trial of supervised exercise regimens and their impact on walking performance, skeletal muscle mass and calpain activity in patients with intermittent claudication.

Authors:  C L Delaney; M D Miller; T K Chataway; J I Spark
Journal:  Eur J Vasc Endovasc Surg       Date:  2014-01-18       Impact factor: 7.069

4.  Rocker-soled shoes and walking distance in patients with calf claudication.

Authors:  J K Richardson
Journal:  Arch Phys Med Rehabil       Date:  1991-07       Impact factor: 3.966

Review 5.  Physical exercise for peripheral vascular disease--a review.

Authors:  E Ernst
Journal:  Vasa       Date:  1987       Impact factor: 1.961

6.  [Programmed physical training in physiotherapy for obliterative arteriopathies of the lower limbs at the stage of claudication (author's transl)].

Authors:  Y C Boutroux; D Baccard; J Y Bouchet
Journal:  J Mal Vasc       Date:  1980

7.  Value of a supervised exercise program for the therapy of arterial claudication.

Authors:  R B Patterson; B Pinto; B Marcus; A Colucci; T Braun; M Roberts
Journal:  J Vasc Surg       Date:  1997-02       Impact factor: 4.268

8.  Improving maximum walking distance in early peripheral arterial disease: randomised controlled trial.

Authors:  Bess Fowler; Konrad Jamrozik; Paul Norman; Yvonne Allen; Eve Wilkinson
Journal:  Aust J Physiother       Date:  2002

9.  Gender differences following supervised exercise therapy in patients with intermittent claudication.

Authors:  Lindy N M Gommans; Marc R M Scheltinga; Marc R H M van Sambeek; Angela H E M Maas; Bianca L W Bendermacher; Joep A W Teijink
Journal:  J Vasc Surg       Date:  2015-09       Impact factor: 4.268

10.  Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial.

Authors:  Sandra Spronk; Johanna L Bosch; Pieter T den Hoed; Hermanus F Veen; Peter M T Pattynama; M G Myriam Hunink
Journal:  J Vasc Surg       Date:  2008-09-04       Impact factor: 4.268

View more
  47 in total

Review 1.  Intermittent Claudication and Asymptomatic Peripheral Arterial Disease.

Authors:  Gerhard Rümenapf; Stephan Morbach; Andrej Schmidt; Martin Sigl
Journal:  Dtsch Arztebl Int       Date:  2020-03-13       Impact factor: 5.594

2.  [Nonpharmacological pain therapy for chronic pain].

Authors:  Corinna Drebenstedt
Journal:  Z Gerontol Geriatr       Date:  2018-10-29       Impact factor: 1.281

Review 3.  Peripheral arterial disease: Scoping review of patient-centred outcomes.

Authors:  Laura Bolton
Journal:  Int Wound J       Date:  2019-10-09       Impact factor: 3.315

Review 4.  Treatment Strategies for the Claudicant.

Authors:  Keith Pereira
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

Review 5.  Update on the pathophysiology and medical treatment of peripheral artery disease.

Authors:  Jonathan Golledge
Journal:  Nat Rev Cardiol       Date:  2022-01-07       Impact factor: 32.419

6.  L'exercice contre la maladie artérielle périphérique.

Authors:  Arthur A Qi; Christina S Korownyk
Journal:  Can Fam Physician       Date:  2022-04       Impact factor: 3.275

7.  Exercise for peripheral artery disease.

Authors:  Arthur A Qi; Christina S Korownyk
Journal:  Can Fam Physician       Date:  2022-04       Impact factor: 3.275

8.  Physical Activity After Treatment for Symptomatic Peripheral Artery Disease.

Authors:  Poghni A Peri-Okonny; Sarthak Patel; John A Spertus; Elizabeth A Jackson; Ali O Malik; Jeremy Provance; Carlos Mena-Hurtado; Mehdi H Shishehbor; Vittal Hijjaji; Kensey L Gosch; Kim G Smolderen
Journal:  Am J Cardiol       Date:  2020-10-13       Impact factor: 2.778

9.  Multimodal Supervised Exercise Training Is Effective in Improving Long Term Walking Performance in Patients with Symptomatic Lower Extremity Peripheral Artery Disease.

Authors:  Barbara Ney; Stefano Lanzi; Luca Calanca; Lucia Mazzolai
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

10.  A systematic review of the role of heat therapy for patients with intermittent claudication due to peripheral artery disease.

Authors:  Amy E Harwood; Christopher Ja Pugh; Charles J Steward; Campbell Menzies; C Doug Thake; Tom Cullen
Journal:  Vasc Med       Date:  2021-02-15       Impact factor: 3.239

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.